?-Lactams are the most widely used class of antibiotics. Since the discovery of benzylpenicillin in the 1920s, thousands of new penicillin derivatives and related ?-lactam classes of cephalosporins, cephamycins, monobactams, and carbapenems have been discovered. Each new class of b-lactam has been developed either to increase the spectrum of activity to include additional bacterial species or to address specific resistance mechanisms that have arisen in the targeted bacterial population. Resistance to ?-lactams is primarily because of bacterially produced ?-lactamase enzymes that hydrolyze the ?-lactam ring, thereby inactivating the drug. The newest effort to circumvent resistance is the development of novel broad-spectrum ?-lactamase inhibitors that work against many problematic ?-lactamases, including cephalosporinases and serine-based carbapenemases, which severely limit therapeutic options.
This report contains market size and forecasts of Beta-lactam and Beta-lactamase Inhibitors in global, including the following market information:
Global Beta-lactam and Beta-lactamase Inhibitors Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Beta-lactam and Beta-lactamase Inhibitors Market Sales, 2017-2022, 2023-2028, (M Units)
Global top five Beta-lactam and Beta-lactamase Inhibitors companies in 2021 (%)
The global Beta-lactam and Beta-lactamase Inhibitors market was valued at 29150 million in 2021 and is projected to reach US$ 33070 million by 2028, at a CAGR of 1.8% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Penicillins Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Beta-lactam and Beta-lactamase Inhibitors include Pfizer, Novartis (Sandoz), TEVA, Merck, AbbVie (Allergan), Sumitomo Dainippon, Hikma, Aurobindo Pharma and Wockhardt, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Beta-lactam and Beta-lactamase Inhibitors manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Beta-lactam and Beta-lactamase Inhibitors Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (M Units)
Global Beta-lactam and Beta-lactamase Inhibitors Market Segment Percentages, by Type, 2021 (%)
Penicillins
Cephalosporins
Carbapenems
Monobactams
Combinations
Global Beta-lactam and Beta-lactamase Inhibitors Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (M Units)
Global Beta-lactam and Beta-lactamase Inhibitors Market Segment Percentages, by Application, 2021 (%)
Oral
Intravenous
Global Beta-lactam and Beta-lactamase Inhibitors Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (M Units)
Global Beta-lactam and Beta-lactamase Inhibitors Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Beta-lactam and Beta-lactamase Inhibitors revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Beta-lactam and Beta-lactamase Inhibitors revenues share in global market, 2021 (%)
Key companies Beta-lactam and Beta-lactamase Inhibitors sales in global market, 2017-2022 (Estimated), (M Units)
Key companies Beta-lactam and Beta-lactamase Inhibitors sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Pfizer
Novartis (Sandoz)
TEVA
Merck
AbbVie (Allergan)
Sumitomo Dainippon
Hikma
Aurobindo Pharma
Wockhardt
Lupin Limited
Fresenius Kabi
B. Braun
USantibiotics
Qilu Pharmaceutical
ACS Dobfar
Nichi-Iko (Sagent)
Antibiotice

LEAVE A REPLY

Please enter your comment!
Please enter your name here